David H. Persing, Executive VP, Chief Med/Tech Officer at CEPHEID (CPHD), sold 46,750 shares at $44.43 ($2.0M) on 2012-02-07, disclosed to the SEC on 2012-02-09.
Scheduled sale ($2.0M) by Executive VP, Chief Med/Tech Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $43.06 | 26,750 | $1.2M | 56.7% |
| 2 | $43.52 | 9,600 | $418K | 20.6% |
| 3 | $44.43 | 400 | $18K | 0.9% |
| 4 | $44.49 | 10,000 | $445K | 21.9% |
| Total | $43.47 avg | 46,750 | $2.0M | 100% |
| Filing → |
| CPHD | SELL | 2014-12-02 | $837K | — | Filing → |
| CPHD | SELL | 2014-12-01 | $4.1M | — | Filing → |
| CPHD | SELL | 2014-11-17 | $273K | — | Filing → |